Arglabin is a natural product with antitumor and anti-inflammatory activity. Arglabin competitively inhibits the binding of farnesyl diphosphate to farnesyl transferase (FTase), preventing the activation of RAS proto-oncogene by preventing the incorporation of farnesyl pyrophosphate into human H-ras proteins. Arglabin is also an inhibitor of the NLRP3 inflammasome. Arglabin reduces inflammation and plasma lipids and has shown a marked reduction in atherosclerotic lesions.